Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion

Journal of Chemotherapy

Volumn 17, Issue 1, 2005, Pages 82-85

  Demartini, G ^a   Lequaglie, C ^b   Brega Massone, P P ^b   Scaglione, F ^a   Fraschini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Humans; Liposomal amphotericin B; Lung tissue distribution

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG METASTASIS; LUNG PARENCHYMA; LUNG RESECTION; MALE; MYCOSIS; THORACOTOMY; TISSUE SECTION;

EID: 16244364796     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.1.82     Document Type: Article

References (22)

1. Holleran WM, Wilbur JR, De Gregorio MW. Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis 1985; 1: 619-624.
2. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother, 1991; 28 (Suppl. B): 93-104.
3. Heinemann V, Jehn U, Scholz P, et al. AmBisome-pharmacokinetic and clinical results. Bone Marrow Transplant, 1993; 12(Suppl.): S147-148.
4. Joly V, Saint-Julien L, Carbon C, Yeni P. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J Pharmacol Exp Ther 1990; 255: 17-22.
5. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother, 1991; 28 (Suppl. B): 83-91.
6. Lequaglie C, Giudice G, Brega Massone PP, Cataldo I. Antifungal therapy in thoracic cancer patients with low dose liposomal Amphotericin B (AmBisome). Int J Antimicrob Agents, 2000; 16: 541-543.
7. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: Efficacy and safety evaluation. Clin Transpl, 1990; 4: 167-175.
8. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1: 272-283.
9. Adler-Moore JP, Proffitt RT. Development, characterisation, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res, 1993; 3: 429-50.
10. Bekersky I, Fielding RM, Dressier DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother, 2002; 46: 828-833.
11. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh T. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother, 2002; 46: 834-840.
12. Janknegt R, de Marie S, Bakker-Woundenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet, 1992; 23: 279-291.
13. Heinemann V, Bosse D, Jehn U, et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J Antimicrob Chemother, 1997; 40: 295-297.
14. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol, 1998; 38: 583-592.
15. Bekersky I, Borwell GW, Hiles R, Fielding RM, Buell DN, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (ambisome): a 91-day study in rats. Pharm Res, 2000; 17: 1494-1502.
16. Matot I, Pizov R. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med, 2000; 18: 2528-2532.
17. 14C] cholesterol-ambisome following a single intravenous administration to rats. Drug Metab Disp, 2001; 29: 681-685.
18. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B deoxycholate. Antimicrob Agents Chemother, 1989; 33: 362-368.
19. Collette N, van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother, 1991; 27: 535-548.
20. Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother, 1997; 41: 1275-1280.
21. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res. 1999; 16: 1694-1701.
22. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis, 1985; 152: 1037-1043.